- Home
- CRBP vs ARAY Comparison
CRBP vs ARAY Comparison
Compare CRBP & ARAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- ARAY
- Stock Information
- Founded
- CRBP 2009
- ARAY 1990
- Country
- CRBP United States
- ARAY United States
- Employees
- CRBP 19
- ARAY N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- ARAY Medical/Dental Instruments
- Sector
- CRBP Health Care
- ARAY Health Care
- Exchange
- CRBP Nasdaq
- ARAY Nasdaq
- Market Cap
- CRBP 158.3M
- ARAY 180.0M
- IPO Year
- CRBP N/A
- ARAY 2007
- Fundamental
- Price
- CRBP $13.00
- ARAY $1.82
- Analyst Decision
- CRBP Strong Buy
- ARAY Strong Buy
- Analyst Count
- CRBP 8
- ARAY 1
- Target Price
- CRBP $62.00
- ARAY $9.00
- AVG Volume (30 Days)
- CRBP 313.3K
- ARAY 659.9K
- Earning Date
- CRBP 11-07-2024
- ARAY 01-29-2025
- Dividend Yield
- CRBP N/A
- ARAY N/A
- EPS Growth
- CRBP N/A
- ARAY N/A
- EPS
- CRBP N/A
- ARAY N/A
- Revenue
- CRBP N/A
- ARAY $444,204,000.00
- Revenue This Year
- CRBP N/A
- ARAY $6.64
- Revenue Next Year
- CRBP N/A
- ARAY $5.69
- P/E Ratio
- CRBP N/A
- ARAY N/A
- Revenue Growth
- CRBP N/A
- ARAY N/A
- 52 Week Low
- CRBP $5.25
- ARAY $1.40
- 52 Week High
- CRBP $61.90
- ARAY $3.05
- Technical
- Relative Strength Index (RSI)
- CRBP 25.10
- ARAY 43.76
- Support Level
- CRBP $12.90
- ARAY $1.75
- Resistance Level
- CRBP $16.21
- ARAY $1.98
- Average True Range (ATR)
- CRBP 0.95
- ARAY 0.09
- MACD
- CRBP -0.16
- ARAY -0.03
- Stochastic Oscillator
- CRBP 1.69
- ARAY 20.51
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About ARAY Accuray Incorporated
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.